SCHEMBL3565041

SCHEMBL3565041

COc1ccc(-c2ccc3c(c2)C(=CNc2ccc(CN4CCCCC4)cc2)C(=O)NC3=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
KMT2A Q03164 1/20 0.46
CDK4 P11802 1/20 0.45
CCND1 P24385 1/20 0.45
CHKA P35790 1/20 0.43
ACP1 P24666 3/20 0.43
MCHR1 Q99705 4/20 0.41
CHRM1 P11229 3/20 0.41
HTR2A P28223 3/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTGIR P43119 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
ABCB1 P08183 1/20 0.40
CLK2 P49760 1/20 0.40
PDGFRB P09619 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565038 1.00 LMNA (0.46) LMNAKMT2ACDK4CCND1CHKA
SCHEMBL13343906 0.93 LMNA (0.48) LMNAKMT2ACDK4CCND1ACP1
SCHEMBL3577954 0.93 LMNA (0.48) LMNAKMT2ACDK4CCND1ACP1
SCHEMBL3577953 0.93 LMNA (0.48) LMNAKMT2ACDK4CCND1ACP1
SCHEMBL3563059 0.92 HRH3 (0.45) MCHR1CHRM1HTR2AKDM4EHRH3
SCHEMBL3563056 0.92 HRH3 (0.45) MCHR1CHRM1HTR2AKDM4EHRH3
SCHEMBL13343932 0.92 HRH3 (0.45) MCHR1CHRM1HTR2AKDM4EHRH3
SCHEMBL3568157 0.92 CDK4 (0.47) LMNAKMT2ACDK4CCND1MCHR1
SCHEMBL3568154 0.92 CDK4 (0.47) LMNAKMT2ACDK4CCND1MCHR1
SCHEMBL3567529 0.91 KMT2A (0.46) LMNAKMT2ACDK4CCND1ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US claimed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US claimed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
EP-1963273-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
WO-2007075783-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR WYETH (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 LMNA 2285/4885KMT2A 1053/4885CDK4 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.